Cited by 723Computational Drug Discovery MethodsMachine Learning in Materials ScienceMachine Learning in Healthcare

Deep Learning in Drug Discovery

Gawehn, Erik, Hiss, Jan A., Schneider, Gisbert·2016·Molecular Informatics

Abstract

Artificial neural networks had their first heyday in molecular informatics and drug discovery approximately two decades ago. Currently, we are witnessing renewed interest in adapting advanced neural network architectures for pharmaceutical research by borrowing from the field of “deep learning”. Compared with some of the other life sciences, their application in drug discovery is still limited. Here, we provide an overview of this emerging field of molecular informatics, present the basic concepts of prominent deep learning methods and offer motivation to explore these techniques for their usefulness in computer‐assisted drug discovery and design. We specifically emphasize deep neural networks, restricted Boltzmann machine networks and convolutional networks.

Integrity signals

Registry

Crossref · 10.1002/minf.201501008

Cites

136 of 136 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The efficacy and toxicity of new drug compounds can be predicted using AI approaches with greater accuracy and efficiency than traditional methods.

    “For instance, the efficacy and toxicity of new drug compounds can be predicted using these approaches, with greater accuracy and efficiency than when using traditional methods [12,13].”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Gawehn, E., Hiss, J. A., & Schneider, G.
Affiliations
ETH Zurich (CH)
Corresponding author
Schneider, Gisbert
Venue
Molecular Informatics
Publisher
Wiley
Published
2015-12-30
Volume
35
Issue
1
Pages
3-14
ISSN
  • 1868-1743 (ISSN-L)
  • 1868-1751
OpenAlex
W2213443318
Cited by
723
References
136
Citations by year
2026: 41 · 2025: 59 · 2024: 69 · 2023: 76 · 2022: 80 · 2021: 85 · 2020: 79 · 2019: 89 · 2018: 87 · 2017: 36 · 2016: 22
FWCI
5.20
Type
journal article
Language
en
Open access
closed
Locations
  • Molecular Informatics (publishedVersion)
  • PubMed (publishedVersion)
Funders
Swiss National Science Foundation (200021_157190, CR32I2_159737)
Topics
  • Physical Sciences › Computer Science › Computational Theory and Mathematics › Computational Drug Discovery Methods
  • Physical Sciences › Materials Science › Materials Chemistry › Machine Learning in Materials Science
  • Physical Sciences › Computer Science › Artificial Intelligence › Machine Learning in Healthcare
Keywords
deep learning, drug discovery, computer-aided drug design, deep neural network, restricted Boltzmann machine, convolutional neural networks, artificial neural networks
MeSH terms
Machine Learning, Artificial Intelligence, Humans, Neural Networks, Computer, Computational Biology, Proteomics, Drug Discovery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review